How accountants deal with a poison pill offer

Introduction
Financial and legal experts concur that one of the strongest anti- takeover defense approaches is a shareholder rights strategy (or, in more informal terms, a poison pill)[footnoteRef:1],[footnoteRef:2]. Though the particulars differ based on strategic implementations, the elementary defense tool offers extant shareholders (with the exception of hostile bidders) the right to purchase stocks authorizing them to obtain new shares at considerably low rates, in case a hostile bidder gets his hands on more than a specific amount of the outstanding shares of the organization[footnoteRef:3]. Consequently, poison pills accord the directorial board the capability of significantly diluting hostile bidders’ ownership stake, according board members effective veto power to suppress hostile acquisition attempts. In this paper, the subject of how accountants handle poison pills will be addressed, including a summary of the poison pill, courts’ response to it, latest attempts at poison pills, and its impacts on organizational value as well as long- term influence on balance sheet and earnings. [1: Martijn Cremers and Allen Ferrell. "Thirty years of shareholder rights and firm value." The Journal of Finance 69, no. 3 (2014): 1167- 1196.] [2: Matthew R. Denes, Jonathan M. Karpoff, and Victoria B. McWilliams. "Thirty years of shareholder activism: A survey of empirical research." Journal of Corporate Finance 44 (2017): 405- 424.] [3: Eliezer M. Fich, Jarrad Harford, and Adam S. Yore. "Does takeover protection matter? Evidence from a natural experiment." Evidence from a Natural Experiment (April 2, 2018) (2018).]
Overview of the poison pill
Poison pills are a type of defense approach target organizations employ for dissuading hostile takeover attempts by acquirers. As suggested by the name, a poison pill approach resembles something hard to tolerate or swallow – targeted organizations adopt such an approach for rendering their shares disadvantageous to acquirers. A poison pill drastically increases acquisition costs, creating large disincentives for entirely deterring such attempts[footnoteRef:4]. Such a tool helps safeguard minority shareholders, besides preventing changes to organizational management or control. However, its implementation doesn’t invariably suggest that the organization is totally against acquisition; it could also be employed for obtaining greater valuation or better acquisition terms. [4: Fred J. Weston, and Kwang S. Chung. "Takeovers and corporate restructuring: An overview." Business Economics (1990): 6- 11.]
The origins of the term, poison pill, may be traced back to the spying and war era, when undercover workers bore poison pills on their person to swallow in the event they were bound for capture. Likewise, target organizations adopt poison pill approaches for preventing hostile takeovers. The earliest usage of the term within the corporate finance domain is attributed to the US[footnoteRef:5]. Such strategies have deliberate harmful impacts for aggressive acquirers bent upon taking over an organization. [5: Richard S. Ruback. "An overview of takeover defenses." In Mergers and acquisitions, pp. 49- 68. University of Chicago Press, 1987.]
With respect to acquisitions and mergers, the poison pill idea was first formulated during the early 80s, for preventing bidding takeover organizations against direct negotiations of share sales with shareholders, coercing them into negotiating only with the directorial board. Poison pills are normally board- issued plans in warrant form or an alternative connected to extant shares[footnoteRef:6]. No other entity in the organization but the board has the right to revoke them. [6: Ibid, at 49- 68]
Organizations employ every means at hand for improving their market share, including acquisitions, mergers, and strategic alliances with fellow organizations belonging to the same sector/ market. Rival firm acquisition is one means of doing away with or decreasing one’s competition in the market. But target organizations’ management team, founding members and owners generally prefer to maintain control over the company for multiple reasons including more lucrative terms, emotional affinity, or greater valuation, among other things[footnoteRef:7]. They might try to quash acquisition offers by rival organizations. In the absence of a favorable reaction on the part of target organizations’ managers, rival firms wishing to acquire the organization might adopt the tactic of taking over the organization through directly approaching corporate shareholders or striving for management replacement to gain approval for the acquisition effort. These tactics are considered hostile attempts at takeover. As shareholders – who, in effect, are company owners – are entitled to give their majority vote in favor of acquisition, target organizations’ management team employs a special poison pill or shareholder rights plan; this is a structural organizational development plan that has particular conditions integrated into it with the specific purpose of foiling take- over attempts. [7: Dana J. Johnson and Nancy L. Meade. "Shareholder wealth effects of poison pills in the presence of anti- takeover amendments." Journal of Applied Business Research 12 (1996): 10- 19.]
The organization known for the earliest application of this approach is Wachtell, Lipton, Rosen, and Kantz. Co- founder, Martin Lipton, came up with this defense approach in a 80s takeover battle. His client – General American Oil – was targeted by T. Boone Pickens. Lipton recommended a reduction in corporate share value through creating an excess of new shares[footnoteRef:8], diluting Pickens’ coveted ownership and dissuading the unwanted acquirer. [8: David S. Newman, "Delaware Serves Shareholders the" Poison Pill": Moran v. Household International, Inc." Boston College Law Review 27, no. 3 (1986): 641.]
Ever since Lipton’s implementation of this approach, a number of approaches have been formulated, all incorporating the common idea of deterring external hostile takeover efforts through making the organization less favorable for acquirers or increasing the power of extant shareholders[footnoteRef:9],[footnoteRef:10]. Both may be achieved through selling inexpensive shares to extant shareholders, thus diluting the equity a hostile acquirer is likely to receive, in addition to increasing equity for extant shareholders. [9: Ibid, at 641] [10: Moran v. Household, 500 A.2d 1346 (Del. 1985).]
The Flip- In Provision
This type of approach entails enabling all shareholders, with the exception of the acquirer, to purchase extra discounted shares. Though regular investors buy additional shares to gain instant profits, this results in the dilution of the share value of acquirer shares. Such purchase rights are accorded to shareholders prior to finalization of the takeover, and are commonly triggered after acquirer accumulation of a specific threshold share percentage of the target organization. To elucidate further, consider that such a poison pill approach is put into place after an acquirer’s purchase of 30% of corporate shares[footnoteRef:11]. After its implementation, all shareholders with the exception of the hostile acquirer are allowed to purchase new discounted shares. With increase in the amount of additional purchased shares, the hostile acquirer’s interest gets increasingly diluted and the bid cost increases. With new shares flooding the market, acquirers’ share value decreases, thus rendering the takeover effort costlier and more challenging. Bidders who know of the possibility of implementation of such an approach might be disinclined to attempt a takeover. These flip- in provisions are typically openly displayed in corporate charters and bylaws, indicating their possible utilization as a defense against takeovers.  [11: Christine Hurt. "The Hostile Poison Pill." UCDL Rev. 50 (2016): 137.]
A Flip- over poison pill
Such a poison pill approach offers the provision (to target organizations’ stockholders) of buying the acquirer’s shares at great discounts, in the event of a successful hostile attempted takeover[footnoteRef:12]. For instance, the shareholder of a target organization might be entitled to purchase the acquirer’s stock at the rate of two- for- one, thus diluting acquiring organization equity. The acquirer firm might get out of proceeding with this type of acquisition if it is able to sense the dilution of its value after acquisition. [12: Ibid, at 137]
Response to the poison pill by the courts
Poison pills’ legitimacy was ambiguous when the idea first emerged during the early part of the 80s. While the Supreme Court of Delaware supported this approach as a lawful defense mechanism within its 1985 Moran v. Household International, Inc. ruling, jurisdictions external to the United States hold that this policy is unlawful and restrict its application. But the majority of financial and legal experts claim that the pill’s legal status outside of Delaware was unclear until individual states implemented poison pill rules which legalized its implementation[footnoteRef:13],[footnoteRef:14],[footnoteRef:15]. Such rules come under the umbrella class of antitakeover regulations passed by several states in the takeover age. Specifically, the main type of alternative antitakeover regulations include business combination acts, fair price acts, control share acquisition acts, and corporate constituency or directors’ duties acts. [13: Emiliano M. Catan and Marcel Kahan. "The law and finance of antitakeover statutes." Stan. L. Rev. 68 (2016): 629.] [14: Matthew D. Cain, Stephen B. McKeon, and Steven Davidoff Solomon. "Do takeover laws matter? Evidence from five decades of hostile takeovers." Journal of Financial Economics124, no. 3 (2017): 464-485.] [15: Jonathan M. Karpoff, and Michael D. Wittry. "Institutional and legal context in natural experiments: The case of state antitakeover laws." The Journal of Finance 73, no. 2 (2018): 657-714.]
The argument typically proffered in defense of the ambiguous standing of poison pills outside of Delaware prior to poison pill regulations’ ratification is: state courts’ rulings nullified its application within the following states from 1986 to 1989[footnoteRef:16]: New York, Georgia, New Jersey, Indiana, Wisconsin, Colorado, and Virginia[footnoteRef:17]. But the doubts raised due to such decisions were temporary, since all states enacted their own poison pill regulations in a short while following the relevant nullifying court ruling. For instance, though the pill’s usage was nullified by the Supreme Court of New York in June of 1988 (in the Bank of New York Co. v. Irving Bank Corp. case)[footnoteRef:18], New York State enacted a poison pill regulation six months later. [16: Supra note 15, at 636] [17: Dynamics Corp. of Am. v. CTS Corp., 637 F. Supp. 406, 409, 416 (N.D. Ill), aff' d 794 F.2d 250 (7th Cir. 1986)] [18: Bank of New York Co. v. Irving Bank Corp., 142 Misc.2d 145, 536 N.Y.S.2d 923 (N.Y.Sup.Ct.1988) (New York law).]
Furthermore, between the years 1986 and 1990, rulings by the state courts supported the upholding, and not the refutation, of the pill’s legitimacy under the state regulations of Maryland, Maine, Minnesota, Michigan, Wisconsin, and Texas. The aforementioned evidence apparently suggests that the pill’s validity was probably clear prior to these decisions; moreover, the pill definitely acquired validity within those states following its acceptance via state court ruling[footnoteRef:19]. [19: Martijn KJ Cremers, Lubomir P. Litov, and Simone M. Sepe. "Staggered boards and long-term firm value, revisited." Journal of Financial Economics 126, no. 2 (2017): 422-444.]
Nevertheless, taking into account the idea that Delaware’s common law has an influence over the organizational regulations of every other state, later Delaware rulings (i.e., rulings after the Moran case) could have had a greater bearing on the pill’s ambiguity for other states as compared to previous rulings by state courts of those same states. Particularly, in autumn 1988, Delaware’s courts issued the following rulings – Grand Metropolitan PLC v. Pillsbury Co. (November 1, 1988)[footnoteRef:20] and City Capital Associates v. Interco Inc. (November 1, 1988)[footnoteRef:21],[footnoteRef:22]– which brought about startling ambiguity with regard to the poison pill’s utilization; however, this mostly impacted the pill’s redemption and not its validity as such[footnoteRef:23]. In both the above rulings, Delaware’s court arrested the continuation in application of visible poison pills preventing unwanted tender offers. This sparked a great deal of comment, even inducing lawyers to advise their clients to close up shop in Delaware and shift elsewhere[footnoteRef:24]. This offers a plausible explanation for why a number of states adopted poison pill regulations between 1988 and 1990, since its feasibility as a sound defense wasn’t guaranteed any longer following Pillsbury and Interco. [20: PLC v. Pillsbury Co.,[1988-89 Transfer Binder] Fed. Sec. L. Rep.(CCH) S 94, 104 (Del. Ch. 1988)] [21: City Capital Assocs. v. Interco Inc., 551 A.2d 787, 790 (Del. Ch. 1988)] [22: Paul L. Regan. "What's Left of Unocal." Del. J. Corp. L. 26 (2001): 947.] [23: Arthur Fleischer, Alexander R. Sussman, and Gail Weinstein. Takeover defense: mergers and acquisitions. Wolters Kluwer, 2017.] [24: Ibid]
The Delaware Court, in its ruling on the Paramount Communications, Inc. v. Time Inc.[footnoteRef:25] case of 1990, reversed the earlier Pillsbury and Interco decisions; this, according to a few analysts, bestows board members with unrestricted authority to simply decline unwanted tender offers. But numerous other commentators hold that Delaware’s jurisprudence with respect to cases of pill redemption continues to be unsettled, and is typically dependent on fact-specific situations with narrow general applicability[footnoteRef:26]. Hence, as Delaware never implemented any poison pill act, it is quite unique in its poison pill standing. But in other states, following the culmination of the first poison pill regulation wave in the year 1990, the categorization of anti- and pro- pill states came to an end; no other poison pill regulation was passed until the year 1995 (this is when the poison pill regulations’ second wave commenced). [25: Paramount Communications, Inc. v. Time Inc., 571 A.2d 1140, 1152-55 (Del. 1990)] [26: Supra note 23]
Recent poison pill attempts
i. Papa John’s International Inc.’s poison pill
In July of 2018, the directorial board of Papa John’s Pizza, one of the biggest pizza delivery chains in the US, voted on a poison pill for hindering ex-founder John Schnatter’s (who was actually forced out of the company) attempts at acquiring control over the organization[footnoteRef:27]. At the time, Schnatter was the organization’s biggest shareholder, owning 30% of Papa John’s’ stock. For repealing all likely attempts at a takeover on the part of Schnatter, the directorial board of Papa John’s implemented one kind of poison pill provision, namely, a Limited Duration Stockholders Rights plan, which accords extant investors (with the exception of Schnatter and the holding company he owns) one right for every common share as dividend distribution. According to the New York Times, this plan would come into operation if John Schnatter and affiliates’ combined stakes in the organization reach 31%, or if anybody buys 15% of common stock before seeking the approval of the directorial board. As Schnatter wasn’t accorded this dividend distribution privilege, this plan successfully rendered a hostile buyout on his part unfavorable, since he would be required to pay double the value for every share of common corporate stock. Thus, the approach dissuaded him from attempting a takeover through purchasing company shares at the market rate. [27: DONNA FUSCALDO, “Papa John's Adopts Poison Pill vs. Founder: WSJ.” Investopedia, (Updated Jul 23, 2018). Accessed 3 April 2019. Available from Investopedia.]
ii. Netflix Inc.
Institutional investor, Carl Icahn, completely surprised Netflix (leading DVD-mailing and video streaming subscription service firm) after getting his hands on ten percent of corporate shares in the year 2012. Netflix’s response was the issuance of a poison pill, which immensely peeved Icahn and caused him to reduce his shares to only 4.5 percent twelve months later. Subsequently, Netflix brought the plan to an end in December of 2013[footnoteRef:28]. [28: Dealbook. “Netflix Adopts Poison Pill.” The New York Times, (NOVEMBER 5, 2012). Accessed 3 April 2019. Available from The New York Times]
Netflix implemented a poison pill approach for safeguarding itself against an unwanted takeover mere days after Icahn, an activist investor, revealed that he had purchased a 10% company stake. This strategy aimed at keeping Icahn, who was not approved of by members of Netflix’s directorial board, from collecting more shares. According to the organization, the idea was safeguarding the organization and its shareholders against attempts at acquiring such control over the organization as was deemed, by directors, to be against its best interests.
The plan endeavored to render the accumulation of a larger number of Netflix shares on the part of Icahn costlier. As part of this plan, the organization issued a right/common share, allowing shareholders to purchase 1/1000th of a share they preferred at 350 dollars per right. However, the rights could only be enjoyed if the investor got hold of 10% company stock without board approval. Additionally, if, upon gaining ?10% (or ?20% for 13G institutional shareholders) of the outstanding common stock of the company, the company merged into some other company, the acquirer merged into the company, or the company transferred or sold over half its earning capacity, assets, or cash flow, then individual rights allow their holder to buy, at exercise rates, several common stock shares of the transacting entity with a then-existing market value of double the exercise rate[footnoteRef:29]. The acquirer cannot exert the above rights. [29: Ibid]
iii. The Avis Budget Group
In January of 2017, car rental service, Avis, prevented SRS Investment, its largest shareholder, from obtaining over 10% voting authority. This strategy was implemented after the latter, which held 9.7% common company stock at that time, declined renewing its agreement (made a year back) which barred it from increasing its already large stake, running proxy contests and undertaking other restrictive means. The company was concerned about its share buyback plans offering hedge funds increased control without premium payments[footnoteRef:30]. SRS was already the owner of a 28.5% economic interest within the company, with around 66% of this percentage being cash-settled alternatives and derivatives. In return for a place on the board and the privilege of recommending a second, independent director, SRS settled for ceasing to take any further action for twelve months in January of 2016. [30: Jeffrey Goldfarb, “At Avis, a Poison Pill Against Creeping Control.” The New York Times, (Jauary 24, 2017). Accessed 3 April 2019. Available from The New York Times.]
No overt friction existed between SRS and Avis, with the firm’s shares gaining 42% in the last year, outstripping the 500-stock index of Standard & Poor to a great degree[footnoteRef:31]. SRS was also not popular as an aggressive investor. What Avis was afraid of is still not clear, as is the reason behind SRS’s deciding against extending its ‘standstill agreement’. [31: Ibid]
iv. Micron Tech Inc.
Micron – the biggest memory chip manufacturer in America – decided to implement a “Poison Pill” approach after anticipating an unwanted takeover. The approach entailed issuing rights which would be activated if a person or a group of persons obtained ?4.99 percent of outstanding organizational stock[footnoteRef:32]. On 25th July, 2016, the company’s shares gained over six percent in trading following “poison pill” plan implementation the prior week. This renewed rumor that the company might be targeted by an acquirer. A regulatory report made seven days prior revealed that the organization claimed its directorial board had ratified a policy for preventing acquisition of five percent of outstanding corporate shares by any group or individual. A dividend was declared that would permit shareholder buying of extra, inexpensive company shares if the person or group accumulated a five-percent organizational ownership stake. [32: Ian King, “Micron Gains as ‘Poison Pill’ Sparks Speculation It’s a Target.” Bloomberg, (July 25, 2016). Accessed 3 April 2019. Available from Bloomberg.]
Micron was often considered to be anticipating a takeover attempt in the time leading up to the aforementioned filing, since the semiconductor sector was witnessing a never-before-seen consolidation trend which involved an increasing number of chip manufacturing firms being acquired. The major part of such speculation revolved around Micron’s potential for acquisition by state-supported Chinese individuals and groups. These entities were known for their aggressive pursuit of Western technological firm acquisitions, especially firms belonging to the semiconductor sector.
The year 2018 witnessed extensive news of Chinese firm, Tsinghua Unigroup Limited, making a twenty-three-billion-dollar Micron acquisition bid[footnoteRef:33]. This deal never happened, with company directors and managers supposedly expressing doubts regarding whether the government of America would ever accept this sort of acquisition. The People’s Republic of China made a public declaration that its national objective was allocating billions towards push-starting its very own semiconductor sector for feeding its huge local electronics market; one top priority was, apparently, memory chip manufacture. However, any effort on the part of Chinese groups to get hold of controlling stakes in Micron Tech Inc. would probably be contested and even disallowed by the CIFUS (Committee on Foreign Investment in the US) for national security reasons. [33: Dylan McGrath. “'Poison Pill' Fuels Speculation of Micron Takeover.” EETimes, (25 July, 2017). Accessed 3 April 2019. Available from eeTimes.]
Effect of talking about a poison pill on the company`s current value and poison pill effects on long term investments (Does a company report more or less profits in its balance sheet after either an adoption or threat of a poison pill (that is, does a company deferring a hostile takeover take action to increase its own earnings, or does the company still putter along))
Organizations with a penchant for poison pill implementation may be categorized based on financial performance. Here, the main question is whether underperformance leads threatened organizations to resort to poison pill strategies or whether the decision stems from corporate governance principles. According to evidence, weak performance will probably be precedent to the formulation of a poison pill plan[footnoteRef:34]. Further, poison pills are typically employed by organizations marked by small ownership positions. Key insights of the economic evaluation encompass: [34: Robert F. Bruner. The poison pill anti-takeover defense: The price of strategic deterrence. Research Foundation of the Institute of Chartered Financial Analysts, 1991.]
· The capacity of the pill to cause harm to a hostile acquirer is largely reliant on the exercise price multiple, which is defined as the exercise price-prevalent stock price ratio. Curiously, financial and legal consultants and courts focus more on other structural pill elements like trigger percentage and purchase value. This analysis indicates that the aforementioned exercise price multiple ought to be the key element of focus.
· Theoretically, a pill is capable of both destroying and creating shareholder value. The result hinges on countervailing effect balance. Implementation of a pill might be indicative of insiders’ belief that the organization has more value as compared to its extant trading price; however, the pill dissuades outsiders from bidding for the organization. The main consideration when gauging pill impact is organizational value under plans excluded by the pill.
· Here, reported numerical simulations and the pool of other relevant studies indicates that this defense mechanism proves expensive to the shareholders of target organizations. The expense is mainly dependent on the ambiguity related to investor predictions of future organizational value and stock rates if restructured. Increased ambiguity has been linked to more adverse impacts of pill implementation.
· Finally, simulation shows that the poison pill works as a highly efficient deterrent. It is never swallowed on purpose, since all logical acquirers would wish to avoid triggering its drastically dilutive impacts. The sole tactical reaction left for an acquirer encountering a corporate poison pill is coercing the directorial board, courts, and shareholders for an annulment – an approach which has, on some occasions in the past, proven effective, though has been increasingly becoming an unpromising modus operandi[footnoteRef:35]. [35: Ibid]
Hence, the strategic discouragement the poison pill accords has negative consequences too. Wise, knowledgeable directors and management must, when making the decision of whether or not to implement or repeal a poison pill, take into careful consideration the advantages and disadvantages a poison pill strategy supposedly has. Likewise, securities experts, fiduciaries, and shareholders ought to cautiously perceive management pill defense development plans. Increased social action by large anti-pill institutional investors is in line with the perception that it is too expensive to strategically deter the pill.
The shareholder welfare hypothesis
Advocates of this theory stress the challenges linked to management of organizations for long-run competitiveness whilst constantly threatened by takeover. Arguably, the threat of takeover results in management concentrating overmuch on the present earnings to the detriment of long-run corporate investments. Apparently, provisions to safeguard against takeover serve to enhance target management power to negotiate more lucrative deals with potential hostile acquirers who aim at getting their hands on organizational assets at excessively cheap rates[footnoteRef:36]. As a reaction to the challenges of company management whilst being continuously threatened by takeover, a sensible management team puts forward and promotes antitakeover provisions for facilitating actions which will be in the organization’s best interests in the future. [36: Duc Giang Nguyen, "The endogeneity of poison pill adoption and unsolicited takeovers." International Journal of Managerial Finance 14, no. 1 (2018): 23-36.]
The managerial welfare hypothesis
Advocates of this theory offer the advice that insulation of management against takeover market rivals for company control (Manne, 1965) may adversely impact long-term competitiveness. The establishment of obstacles to market competition for control over the organization might result in entrenched managers with lower incentives for lowering expenses, allocating funds to long lead-time projects and improving efficiency[footnoteRef:37]. As a result, organizations’ long-term competitiveness might be compromised. Those against anti-takeover measures suggest that such measures are put forward and advocated by devious or incompetent managers as a means of insulating management from essential takeover market competition that, if permitted to work as it should, would result in the replacement of these managers. [37: Supra note, at 34]
Cross-sectional Variations in Changes in Long-term Investment
A key point to emphasize at this juncture is, the aforementioned theories may not be utilized for predicting the sign (negative or positive) of long-run investment modifications. The challenges with the interpretation of resultant long-run investment changes of organizations implementing antitakeover measures arises from the absence of consensus with regard to the correct degree of corporate investment. Literature cites two conflicting long-run investment theories[footnoteRef:38], of which one indicates that a growth in long-run discretionary expenses results in positive shareholder capital, since organizations undertake positive NPV (net present value) projects for benefiting shareholders. [38: Ibid]
It has been suggested by a conflicting theory that greater long-run discretionary expenses are related to reduction in shareholder wealth, particularly for organizations whose cash flows go beyond those needed for financing every positive NPV venture[footnoteRef:39]. Hence, taking into account the two aforementioned contradictory opinions with regard to long-run expenses, an analysis of resultant long-run investment expense changes by themselves (as performed in earlier research works) is unable to determine whether or not management functions in shareholders’ best interests. [39: Supra note 19, at 422-444.]
If a shadow poison pill functions as a tool promoting commitment, which better allows directorial board members to take into consideration organizational stakeholders’ long-run interests, as the bonding theory indicates, then the poison pill regulations would be more important in case of innovation-intense companies. In fact, innovation typically calls for company-specific investments on the part of strategic partners, key employees, clients and suppliers[footnoteRef:40]. Hence, shadow pills could help put a stop to the actual result-based expropriation of stakeholders’ organization-specific investments within companies more involved in informationally complicated or inventive business ventures. [40: Simon Deakin, and Giles Slinger. "Hostile takeovers, corporate law, and the theory of the firm." JL & Soc'y 24 (1997): 124.]
The way accountants handle a poison pill is mostly reliant on the underlying reason for its application. Poison pill agendas differ for different investors, and concentrate on distinct aspects such as cost-cutting, re-organization, increased leverage, company spin-offs, refurbished financial systems, and a greater number of shareholder-oriented applications of liquidity and funds for achieving increased business value within public markets[footnoteRef:41]. [41: Thomas A. Turk, Jeremy Goh, and Candace E. Ybarra. "THE EFFECT OF TAKEOVER DEFENSES ON LONG TERM AND SHORT TERM ANALYSTS’EARNINGS FORECASTS: THE CASE OF POISON PILLS." Corporate Ownership and Control4, no. 4 (2007): 127-131.]
Net operating loss (NOL) poison pill
This poison pill approach is a variant of the conventional poison pill strategies. NOL protection offers alternative poison pill applications. Contrary to the conventional poison pill’s takeover defense intent, the key goal of NOL poison pills is safeguarding tax assets. Though closely resembling conventional poison pill approaches, NOL poison pill approaches are different from the former from one key structural perspective[footnoteRef:42]. NOL poison pill approaches are activated at significantly smaller levels of shareholder ownership. The conventional poison pill was legally allowed for long, but it was only after Selectica that courts determined whether or not NOL poison pill strategies’ aims and low trigger were acceptable. [42: Sarah Webber and Karie Davis-Nozemack. "NOL Poison Pills: Using Corporate Law for Tax Purposes." Accounting Faculty Publications. Paper 57. (2012). 1-12]
Section 172 provides organizations with a type of earnings that averages through helping companies offset prior or future earnings with NOLs. The employment of NOL carrybacks facilitates the formulation of earlier years’ tax refunds through offsetting earlier earnings with extant NOLs. It is normally possible to carry back NOLs for a couple of years, and carry them forward for a couple of decades[footnoteRef:43]. Instead of utilizing a carryback, organizations may choose to utilize a yearly irreversible carry-forward. Company NOLs are computed as follows: gross earnings less deductions; however, they encompass unlimited dividend received deduction, whilst excluding both past NOLs and all local production deductions. [43: Ibid]
Though organizations might utilize NOLs for offsetting earnings and potentially creating tax refunds, the use of NOL is dependent on companies’ capability of generating money or otherwise by employing an NOL. In case of NOL carry-forwards, NOLs’ usefulness and worth depend on future circumstances. NOLs’ perceived worth in the form of an asset has been demonstrated by financial reports. Financial accounting regulations allow NOLs to be documented on company balance sheet in the form of deferred tax assets under the FASB ASC 740 owing to its expected long-run tax savings[footnoteRef:44]. NOL deferred tax assets are valued as gross NOL amounts times effective rate of tax, unless there are concerns for long-term realization or past negative evidence. An extensive record of loss or colossal loss may be proof of weakened usage. Therefore, organizations might carry their NOLs at marginal or considerably decreased values. NOL use is marked by certainty but the potential value of the NOL provides organizations’ directorial boards with the incentive to maintain it for potential use in the future. [44: Ibid]
Conclusion
A poison pill approach is a controversial tool. But researchers provide explicit proofs supporting the theory of shareholder wealth maximization. Poison pills positively affect shareholder value since compelling abnormal returns are exhibited by the market model. This is a sound finding for the CRSP Equally Weighted Index, S&P 500, and CRSP Weighted Index in the form of market benchmark alternatives. Further, the Fama-French-momentum factor model reveals outcomes are sound and not biased by the model. Controlling for different sub-periods results in insights that extant economic situations affect stock price response. But positive market response to implementation of poison pills remains sound for all time frames. Additional examinations suggest a poor market response to regular measure implementation cases, though the threat of hostile takeover results in huge abnormal returns. Interestingly, this is the case when organizations have shortly signed friendly pacts. Although shareholders don’t attach much importance to isolation from extrinsic company control market forces, they appear to be against attempted hostile takeover. Overall, early findings reveal negative market response to implementation of poison pills. More recent researches reveal a trend of positive market response. Considering all proofs together, it may be concluded that positive abnormal poison pill implementation-connected market returns exist; hence, clearly, the shareholder maximization theory is supported. Poison pills positively impact shareholder value.
References
Journal Articles
Bruner, Robert F. The poison pill anti-takeover defense: The price of strategic deterrence. Research Foundation of the Institute of Chartered Financial Analysts, 1991.
Cain, Matthew D., Stephen B. McKeon, and Steven Davidoff Solomon. "Do takeover laws matter? Evidence from five decades of hostile takeovers." Journal of Financial Economics124, no. 3 (2017): 464-485.
Catan, Emiliano M., and Marcel Kahan. "The law and finance of antitakeover statutes." Stan. L. Rev. 68 (2016): 629.
Cremers, KJ Martijn, Lubomir P. Litov, and Simone M. Sepe. "Staggered boards and long-term firm value, revisited." Journal of Financial Economics 126, no. 2 (2017): 422-444.
Cremers, Martijn, and Allen Ferrell. "Thirty years of shareholder rights and firm value." The Journal of Finance 69, no. 3 (2014): 1167-1196.
Deakin, Simon, and Giles Slinger. "Hostile takeovers, corporate law, and the theory of the firm." JL & Soc'y 24 (1997): 124.
Denes, Matthew R., Jonathan M. Karpoff, and Victoria B. McWilliams. "Thirty years of shareholder activism: A survey of empirical research." Journal of Corporate Finance 44 (2017): 405-424.
Fich, Eliezer M., Jarrad Harford, and Adam S. Yore. "Does takeover protection matter? Evidence from a natural experiment." Evidence from a Natural Experiment (April 2, 2018) (2018).
Fleischer, Arthur, Alexander R. Sussman, and Gail Weinstein. Takeover defense: mergers and acquisitions. Wolters Kluwer, 2017.
Hurt, Christine. "The Hostile Poison Pill." UCDL Rev. 50 (2016): 137.
Johnson, Dana J., and Nancy L. Meade. "Shareholder wealth effects of poison pills in the presence of anti-takeover amendments." Journal of Applied Business Research 12 (1996): 10-19.
Karpoff, Jonathan M., and Michael D. Wittry. "Institutional and legal context in natural experiments: The case of state antitakeover laws." The Journal of Finance 73, no. 2 (2018): 657-714.
Newman, David S. "Delaware Serves Shareholders the" Poison Pill": Moran v. Household International, Inc." Boston College Law Review 27, no. 3 (1986): 641.
Nguyen, Duc Giang. "The endogeneity of poison pill adoption and unsolicited takeovers." International Journal of Managerial Finance 14, no. 1 (2018): 23-36.
Regan, Paul L. "What's Left of Unocal." Del. J. Corp. L. 26 (2001): 947.
Ruback, Richard S. "An overview of takeover defenses." In Mergers and acquisitions, pp. 49-68. University of Chicago Press, 1987.
Turk, Thomas A., Jeremy Goh, and Candace E. Ybarra. "THE EFFECT OF TAKEOVER DEFENSES ON LONG TERM AND SHORT TERM ANALYSTS’EARNINGS FORECASTS: THE CASE OF POISON PILLS." Corporate Ownership and Control 4, no. 4 (2007): 127-131.
Webber, Sarah, and Karie Davis-Nozemack. "NOL Poison Pills: Using Corporate Law for Tax Purposes." Accounting Faculty Publications. Paper 57. (2012). 1-12
Weston, J. Fred, and Kwang S. Chung. "Takeovers and corporate restructuring: An overview." Business Economics(1990): 6-11.
Online source
Dealbook. “Netflix Adopts Poison Pill.” The New York Times, (NOVEMBER 5, 2012). Accessed 3 April 2019. Available from The New York Times.
FUSCALDO, DONNA. “Papa John's Adopts Poison Pill vs. Founder: WSJ.” Investopedia, (Updated Jul 23, 2018). Accessed 3 April 2019. Available from Investopedia.
Goldfarb, Jeffrey. “At Avis, a Poison Pill Against Creeping Control.” The New York Times, (Jauary 24, 2017). Accessed 3 April 2019. Available from The New York Times.
King, Ian. “Micron Gains as ‘Poison Pill’ Sparks Speculation It’s a Target.” Bloomberg, (July 25, 2016). Accessed 3 April 2019. Available from Bloomberg.
McGrath, Dylan. “'Poison Pill' Fuels Speculation of Micron Takeover.” EETimes, (25 July, 2017). Accessed 3 April 2019. Available from EETimes.
Case law
Bank of New York Co. v. Irving Bank Corp., 142 Misc.2d 145, 536 N.Y.S.2d 923 (N.Y.Sup.Ct.1988) (New York law).
City Capital Assocs. v. Interco Inc., 551 A.2d 787, 790 (Del. Ch. 1988)
Dynamics Corp. of Am. v. CTS Corp., 637 F. Supp. 406, 409, 416 (N.D. Ill), aff' d 794 F.2d 250 (7th Cir. 1986)
Moran v. Household, 500 A.2d 1346 (Del. 1985).
Paramount Communications, Inc. v. Time Inc., 571 A.2d 1140, 1152-55 (Del. 1990)
PLC v. Pillsbury Co.,[1988-89 Transfer Binder] Fed. Sec. L. Rep.(CCH) S 94, 104 (Del. Ch. 1988)